• Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

In a bioinformatic search for agents that alter the hepatocellular carcinoma (HCC)-specific gene expression pattern, researchers identified the anthelmintic drug niclosamide as a potential anti-tumor agent, described in the June issue of Gastroenterology. Niclosamide and its ethanolamine salt (NEN), with greater bioavailability, slowed growth of genetically induced liver tumors and

Read more
  • What are the Different Types of Liver Cancer, and How do They Develop?

What are the Different Types of Liver Cancer, and How do They Develop?

A review article in the March issue of Gastroenterology discusses different hypotheses about the cells responsible for liver tumorigenesis. The article also reviews the different classes of liver tumors, based on the molecular features, and how these affect patient prognosis. Daniela Sia et al describe the distinct molecular and clinical features of hepatocellular

Read more
  • How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

Researchers have developed a patient-derived cell line-based model to study how intratumor heterogeneity affects sensitivity of hepatocellular carcinoma (HCC) to different therapeutic agents, reported in the January issue of Gastroenterology. HCCs have a large amount of genetic heterogeneity within each tumor, making them difficult to treat. Multiple regions of tumors

Read more
  • What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

Using 2 powerful high-throughput in vivo screening tools, researchers identified and validated 27 genes as suppressors of hepatocellular carcinoma (HCC), reported in the August issue of Gastroenterology. Their findings support the role of Ras signaling in development of HCC and provide new therapeutic targets. Sorafenib is the only treatment for patients

Read more
  • As Incidence and Deaths from Other Cancers Decrease, Liver Cancer Increases in US

As Incidence and Deaths from Other Cancers Decrease, Liver Cancer Increases in US

Deaths from almost all cancers in the United States decreased from 1975 to 2012—except for liver cancer. In the Annual Report to the Nation on the Status of Cancer, 1975–2012, published online by the National Cancer Institute, A. Blythe Ryerson et al report that the overall cancer death rates for

Read more

How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?

For patients with chronic Hepatitis C virus infection, high levels of α-fetoprotein after therapy can identify those at risk for hepatocellular carcinoma (HCC), researchers report in the July issue of Clinical Gastroenterology and Hepatology. In persons with chronic HCV infection, lack of sustained virologic response (SVR) 24 weeks after the end

Read more

Meeting Report: 20th International Symposium on Hepatitis C Virus and Related Viruses

Didn’t make it to the 20th International Symposium on HCV and Related Viruses last fall in Melbourne, Australia? No worries—you can read a summary of the key findings presented at the meeting in the July issue of Gastroenterology. Michael R. Beard et al. report on the latest research into viral entry, replication, and

Read more

Why are Some Immunized Children Still At Risk for HBV Infection?

Despite immunization, children born to mothers with replicating HBV (marked by hepatitis B e antigen, or HBeAg) are still at risk for infection, according to the April issue of Gastroenterology. Mother-to-infant transmission is the major cause of hepatitis B virus (HBV) infection among immunized children. There have been proposals to

Read more

What Factors Predict Recovery From Chronic HBV Infection?

A low and rapidly decreasing level of Hepatitis B surface antigen (HBsAg) is a good sign for patients with chronic HBV infection, according to the March issue of Clinical Gastroenterology and Hepatology. Tracking progression of chronic HBV infection can be complicated—patients can have high viral loads with no symptoms, and

Read more